Correlation of Pretreatment Proliferative Activity of Breast Cancer With the Response to Cytotoxic Chemotherapy

Remvikos, Yorghos; Beuzeboc, Philippe; Zajdela, A; Voillemot, N.; Magdelénat, H.; Pouillart, P

doi:10.1093/jnci/81.18.1383

Cited by 151 publications

(52 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Highly proliferative breast tumours are associated with shorter patient survival. Studies have suggested that highly proliferative tumours show increased sensitivity to neoadjuvant (Remvikos et al, 1989) and adjuvant chemotherapy (Simpson et al, 2000), regardless of the impact of such treatment on patient survival. In contrast, the rationale of chemotherapy for slowly proliferating tumours is controversial (Wenger and Clark, 1998).…”

Section: Discussionmentioning

confidence: 99%

Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis

et al. 2004

View full text Add to dashboard Cite

Among new biological markers that could become useful prognostic factors for lung carcinoma, Ki-67 is a nuclear protein involved in cell proliferation regulation. Some studies have suggested an association between Ki-67 and poor survival in lung cancer patients. In order to clarify this point, we have performed a systematic review of the literature, using the methodology already described by our Group, the European Lung Cancer Working Party. In total, 37 studies, including 3983 patients, were found to be eligible. In total, 49% of the patients were considered as having a tumour positive for the expression of Ki-67 according to the authors cutoff. In all, 29 of the studies dealt with non-small-cell lung carcinoma (NSCLC), one with small-cell carcinoma (SCLC), two with carcinoid tumours and five with any histology. In terms of survival results, Ki-67 was a bad prognosis factor for survival in 15 studies while it was not in 22. As there was no statistical difference in quality scores between the significant and nonsignificant studies evaluable for the meta-analysis, we were allowed to aggregate the survival results. The combined hazard ratio for NSCLC, calculated using a random-effects model was 1.56 (95% CI: 1.30 -1.87), showing a worse survival when Ki-67 expression is increased. In conclusion, our meta-analysis shows that the expression of Ki-67 is a factor of poor prognosis for survival in NSCLC.

show abstract

Section: Discussionmentioning

confidence: 99%

Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis

et al. 2004

View full text Add to dashboard Cite

show abstract

“…However, little is known about tumour-related factors which might predict CT response in STS. In several other tumours a high proliferation rate has been shown to be one of the factors increasing responsiveness to CT (Mattern et al, 1986;Remvikos et al, 1989;O'Reilly et al, 1992;Hietanen et al, 1995).…”

mentioning

confidence: 99%

A high proliferation rate measured by cyclin A predicts a favourable chemotherapy response in soft tissue sarcoma patients

et al. 1999

View full text Add to dashboard Cite

A small but not insignificant number of patients experience a prolonged survival after treatment of metastatic soft tissue sarcoma. This must be weighed against the majority of the patients who benefit little from the therapy, but nevertheless experience its side-effects. It would therefore be of utmost importance to be able to screen for those patients who respond to the treatment. Since proliferating cells are more sensitive to chemotherapy than non-proliferative cells, we measured the proliferation rate of the primary tumour of 55 soft tissue sarcoma patients with locally advanced or metastatic disease by determining the flow cytometric S phase fraction and immunohistochemical Ki-67 and cyclin A scores. S phase fraction or Ki-67 score did not predict chemotherapy response or progression-free survival. A high cyclin A score, however, correlated with a better chemotherapy response ( P = 0.02) and longer progression-free survival time ( P = 0.04). Our results suggest that a high cyclin A score predicts chemotherapy sensitivity. © 1999 Cancer Research Campaign

show abstract

“…In a previous study of 60 patients, we observed that the pretreatment S-phase fraction was correlated with regression of the tumour mass after the administration of neoadjuvant chemotherapy (Remvikos et al, 1989). Cell cycle modifications analysed by flow cytometry during neoadjuvant chemotherapy, most frequently conceming S-phase and G2M accumulation, were correlated with the efficacy of cytotoxic chemotherapy in a series of 71 patients .…”

Section: Discussionmentioning

confidence: 72%

Plasminogen activator inhibitor-1 (PAI-1) is not related to response to neoadjuvant chemotherapy in breast cancer

Pierga

Laine-Bidron²,

Beuzeboc³

et al. 1997

Br J Cancer

View full text Add to dashboard Cite

Summary There is no information available on the relation between response to chemotherapy and the high-risk phenotype assessed by uPA and/or PAI-1. The clinical situation of neoadjuvant chemotherapy provides a means of rapidly assessing the sensitivity of the primary tumour to cytotoxic drug regimens. The goal of the study was to assess prospectively the predictive value of PAI-1 for response to first-line chemotherapy. PAI-1 concentration was measured on hypertonic cytosolic extracts (0.4 M potassium chloride) by ELISA before chemotherapy on a drill biopsy sample of the tumour in 69 T2 and T3 breast cancer patients (median age 46 years). Oestrogen receptor (ER) (51% ER+), progesterone receptor (PR) (58% PR+), S-phase (median 4.0%) and ploidy were also assessed in the majority of cases. The clinical response to treatment was evaluated after four cycles of FAC or FEC regimen (5-fluorouracil, epidoxorubicin or doxorubicin and cyclophosphamide) (one cycle every 4th week). PAI-1 could be assayed in 29 post-chemotherapy surgical samples. The objective response rate (complete response plus partial response) was 59% (41 out of 69). PAI-1 expressed as gram of tissue (range 19-2370 ng g-1 tissue) was highly correlated (r = 0.98) to PAI-1 expressed as mg protein (range 0.5-68 ng mg-1 protein). No correlation between PAI-1 level and response could be observed, with any cut-off. The post-and pre-chemotherapy PAI-1 levels were correlated (r = 0.66). Of all biological parameters, only high S-phase (cut-off 5%) was slightly correlated (X2 = 3.91, P = 0.05) to response. These data suggest that PAI-1 is not a predictive marker of response to chemotherapy in breast cancer and that its level is not altered by neoadjuvant chemotherapy.

show abstract

Correlation of Pretreatment Proliferative Activity of Breast Cancer With the Response to Cytotoxic Chemotherapy

Cited by 151 publications

References 0 publications

Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis

Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis

A high proliferation rate measured by cyclin A predicts a favourable chemotherapy response in soft tissue sarcoma patients

Plasminogen activator inhibitor-1 (PAI-1) is not related to response to neoadjuvant chemotherapy in breast cancer

Contact Info

Product

Resources

About